• Recursion Pharmaceuticals Inc RXRX.OQ reported a quarterly adjusted loss of 53 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -42 cents. The mean expectation of eight analysts for the quarter was for a loss of 43 cents per share. Wall Street expected results to range from -70 cents to -36 cents per share.

• Revenue fell 58.6% to $4.51 million from a year ago; analysts expected $19.04 million.

• Recursion Pharmaceuticals Inc's reported EPS for the quarter was a loss of 53 cents​.

• The company reported a quarterly loss of $178.91 million.

• Recursion Pharmaceuticals Inc shares had risen by 13.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $10.00

This summary was machine generated from LSEG data February 28 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)